Surrozen, Inc. (NASDAQ:SRZN) VP Sells $14,642.91 in Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 843 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $17.37, for a total transaction of $14,642.91. Following the transaction, the vice president now owns 13,345 shares of the company’s stock, valued at approximately $231,802.65. The trade was a 5.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Surrozen Stock Down 16.4 %

Shares of NASDAQ:SRZN traded down $2.79 during midday trading on Monday, reaching $14.23. The company’s stock had a trading volume of 197,851 shares, compared to its average volume of 168,984. Surrozen, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $18.17. The firm has a 50 day moving average price of $10.92 and a two-hundred day moving average price of $9.90.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.77) by $2.33. The business had revenue of $10.00 million during the quarter. Equities research analysts predict that Surrozen, Inc. will post -7.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Guggenheim raised shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Friday.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Stonepine Capital Management LLC increased its stake in Surrozen by 66.5% in the third quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock valued at $1,318,000 after purchasing an additional 43,916 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Surrozen in the 2nd quarter valued at about $2,050,000. CVI Holdings LLC bought a new stake in Surrozen in the 2nd quarter valued at about $711,000. Finally, Armistice Capital LLC acquired a new position in Surrozen during the 2nd quarter worth approximately $2,080,000. 66.57% of the stock is owned by institutional investors.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.